Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study
Titel:
Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study
Auteur:
Launay, Odile Artaud, Cécile Lachâtre, Marie Ait-Ahmed, Mohand Klein, Jelle Luong Nguyen, Liem Binh Durier, Christine Jansen, Bastiaan Tomberger, Yvonne Jolly, Nathalie Grossmann, Anna Tabbal, Houda Brunet, Jérémy Gransagne, Marion Choucha, Zaineb Batalie, Damien Delgado, Ana Müllner, Matthias Tschismarov, Roland Berghmans, Pieter-Jan Martin, Annette Ramsauer, Katrin Escriou, Nicolas Gerke, Christiane
Verschenen in:
EBioMedicine
Paginering:
Jaargang 75 () nr. C pagina's p.
Jaar:
2022
Inhoud:
Uitgever:
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA, The Author(s)